Declining prevalence of coronary artery disease in incident dialysis patients over the past two decades

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 6, 2014, Pages 593-604

  Iwasaki, Masaki ^a   Joki, Nobuhiko ^a   Tanaka, Yuri ^a   Hayashi, Toshihide ^a   Kubo, Shun ^a   Asakawa, Takasuke ^a   Matsukane, Ai ^a   Takahashi, Yasunori ^b   Hirahata, Koichi ^c   Imamura, Yoshihiko ^b   Hase, Hiroki ^a  

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^b Nissan Tamagawa Hospital   (Japan)

^c Hirahata Clinic   (Japan)

Author keywords

Cardiovascular atherosclerosis; Chronic kidney disease; Erythropoietin stimulating agents; Renin angiotensin aldosterone system inhibitors; Statin

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL PERFUSION IMAGING; PREVALENCE; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTOLIC BLOOD PRESSURE; BLOOD; BODY MASS; COMPLICATION; DIABETIC NEPHROPATHY; INCIDENCE; JAPAN; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; RISK; STATISTICAL MODEL;

AGED; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INCIDENCE; JAPAN; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; RENAL DIALYSIS;

EID: 84903206226     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.21337     Document Type: Article

References (34)

1. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN et al: Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J, 2010; 31: 703-711
2. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis, 2005; 45(4 Suppl 3): S1-153
3. Nakai S, Masakane I, Akiba T, Shigematsu T, Yamagata K, Watanabe Y, Iseki K, Itami N, Shinoda T, Morozumi K et al: Overview of regular dialysis treatment in Japan as of 31 December 2006. Ther Apher Dial, 2008; 12: 428-456
4. Joki N, Hase H, Nakamura R, Yamaguchi T: Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant, 1997; 12: 718-723
5. Ohtake T, Kobayashi S, Moriya H, Negishi K, Okamoto K, Maesato K, Saito S: High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol, 2005; 16: 1141-1148
6. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis, 2004; 43(5 Suppl 1): S1-290
7. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis, 2003; 41(4 Suppl 3): I-IV, S1-91
8. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T et al: Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol, 2009; 54: 293-302
9. Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Murakami M, Hirose E, Sato S et al: Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol, 2010; 55: 976-982
10. Moroi M, Tamaki N, Nishimura M, Haze K, Nishimura T, Kusano E, Akiba T, Sugimoto T, Hase H, Hara K et al: Association between abnormal myocardial fatty acid metabolism and cardiac-derived death among patients undergoing hemodialysis: results from a cohort study in Japan. Am J Kidney Dis, 2013; 61: 466-475
11. Hase H, Tsunoda T, Tanaka Y, Takahashi Y, Imamura Y, Ishikawa H, Inishi Y, Joki N: Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int, 2006; 70: 1142-1148
12. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis, 2009; 53: 982-992
13. Mazzanti M, Germano G, Kiat H, Kavanagh PB, Alexanderson E, Friedman JD, Hachamovitch R, Van Train KF, Berman DS: Identification of severe and extensive coronary artery disease by automatic measurement of transient ischemic dilation of the left ventricle in dual-isotope myocardial perfusion SPECT. J Am Coll Cardiol, 1996; 27: 1612-1620
14. Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, Kimata N, Shigematsu T, Shinoda T, Syouji T et al: Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial, 2010; 14: 505-540
15. Nauta ST, van Domburg RT, Nuis RJ, Akkerhuis M, Deckers JW: Decline in 20-year mortality after myocardial infarction in patients with chronic kidney disease: evolution from the prethrombolysis to the percutaneous coronary intervention era. Kidney Int, 2013; 84: 353-358
16. Maruyama M, Ohira T, Imano H, Kitamura A, Kiyama M, Okada T, Maeda K, Yamagishi K, Noda H, Ishikawa Y et al: Trends in sudden cardiac death and its risk factors in Japan from 1981 to 2005: the Circulatory Risk in Communities Study (CIRCS). BMJ Open, 2012; 2: e000573
17. Shiga Y, Miura S, Mitsutake R, Kawamura A, Uehara Y, Saku K: Significance of serum high-density lipoprotein cholesterol levels for diagnosis of coronary stenosis as determined by MDCT in patients with suspected coronary artery disease. J Atheroscler Thromb, 2010; 17: 870-878
18. Momiyama Y, Ohmori R, Fayad ZA, Tanaka N, Kato R, Taniguchi H, Nagata M, Ohsuzu F: The LDL-cholesterol to HDL-cholesterol ratio and the severity of coronary and aortic atherosclerosis. Atherosclerosis, 2012; 222: 577-580
19. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL et al: Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA, 2007; 297: 499-508
20. Tani S, Nagao K, Hirayama A: HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol. Am J Cardiovasc Drugs, 2011; 11: 411-417
21. Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y: Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol, 2011; 6: 1112-1120
22. Silverstein DM: Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol, 2009; 24: 1445-1452
23. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol, 2005, 16 Suppl 1: S83-88
24. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int, 1999; 55: 1899-1911
25. Joki N, Hase H, Tanaka Y, Takahashi Y, Saijyo T, Ishikawa H, Inishi Y, Imamura Y, Hara H, Tsunoda T et al: Relationship between serum albumin level before initiating haemodialysis and angiographic severity of coronary atherosclerosis in end-stage renal disease patients. Nephrol Dial Transplant, 2006; 21: 1633-1639
26. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A, 1994; 91: 3974-3978
27. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL: Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation, 2003; 108: 79-85
28. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS et al: A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest, 2003; 112: 999-1007
29. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI: Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A, 2003; 100: 11612-11617
30. Weir MR, Dzau VJ: The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens, 1999; 12(12 Pt 3): 205S-213S
31. Jacoby DS, Rader DJ: Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med, 2003; 163: 1155-1164
32. Singh BM, Mehta JL: Interactions between the reninangiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med, 2003; 163: 1296-1304
33. Waseda K, Ozaki Y, Takashima H, Ako J, Yasukawa T, Ismail TF, Hishida H, Ito T: Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis: an intravascular ultrasound study. Circ J, 2006; 70: 1111-1115
34. Boudreau RJ, Strony JT, duCret RP, Kuni CC, Wang Y, Wilson RF, Schwartz JS, Castaneda-Zuniga WR: Perfusion thallium imaging of type I diabetes patients with end stage renal disease: comparison of oral and intravenous dipyridamole administration. Radiology, 1990; 175: 103-105